| Sean Malarkey, | |
|
1100 Reid Pkwy Ste 215, Richmond, IN 47374-1157 | |
| (765) 939-9331 | |
| (765) 939-9314 |
| Full Name | Sean Malarkey |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 9 Years |
| Location | 1100 Reid Pkwy Ste 215, Richmond, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760879308 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reid Hospital & Health Care Services | Richmond, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Reid Physician Associates, Inc. | 6406910769 | 338 |
News Archive
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).
A recent study from Boston University School of Medicine and Boston Medical Center shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe sepsis enrolled in clinical trials, researchers found that in-hospital mortality rates decreased from 47 percent between 1991 and 1995 to 29 percent between 2006 and 2009, a time period when no new pharmacological treatments were developed for severe sepsis.
Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
› Verified 9 days ago
| Entity Name | Reid Physician Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265689111 PECOS PAC ID: 6406910769 Enrollment ID: O20090130000573 |
News Archive
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).
A recent study from Boston University School of Medicine and Boston Medical Center shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe sepsis enrolled in clinical trials, researchers found that in-hospital mortality rates decreased from 47 percent between 1991 and 1995 to 29 percent between 2006 and 2009, a time period when no new pharmacological treatments were developed for severe sepsis.
Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sean Malarkey, 1100 Reid Parkway, Medical Staff Services, Richmond, IN 47374 Ph: (765) 935-8802 | Sean Malarkey, 1100 Reid Pkwy Ste 215, Richmond, IN 47374-1157 Ph: (765) 939-9331 |
News Archive
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).
A recent study from Boston University School of Medicine and Boston Medical Center shows a significant decrease in severe sepsis mortality rates over the past 20 years. Looking at data from patients with severe sepsis enrolled in clinical trials, researchers found that in-hospital mortality rates decreased from 47 percent between 1991 and 1995 to 29 percent between 2006 and 2009, a time period when no new pharmacological treatments were developed for severe sepsis.
Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
› Verified 9 days ago
Joshua R French, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1050 Reid Pkwy, 120, Richmond, IN 47374 Phone: 765-962-6053 Fax: 765-935-7401 | |
Brian Kwong, D.O. Surgery Medicare: Medicare Enrolled Practice Location: 1100 Reid Pkwy Ste 215, Richmond, IN 47374 Phone: 765-939-9331 | |
Christopher Moore, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1050 Reid Pkwy, Suite 120, Richmond, IN 47374 Phone: 765-962-6053 Fax: 765-935-7401 | |
Mr. Joshua A Wilensky, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 Reid Pkwy Ste 215, Richmond, IN 47374 Phone: 765-939-9331 Fax: 765-939-9314 | |
Ashley Nicole Mikesell, PA-C Surgery Medicare: Accepting Medicare Assignments Practice Location: 1911 Chester Blvd, Richmond, IN 47374 Phone: 765-962-4872 | |
Bradford J Barrett, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2248 Glen Eagle Way, Richmond, IN 47374 Phone: 765-935-5600 |